Drug solubility in fatty acids as a formulation design approach for lipid-based formulations: a technical note / Yung-Chi Lee, Chad Dalton, Brian Regler, David Harris
Abstract Lipid-based drug delivery systems have been intensively investigated as a means of delivering poorly water-soluble drugs. Upon ingestion, the lipases in the gastrointestinal tract digest lipid ingredients, mainly triglycerides, within the formulation into monoglycerides and fatty acids. While numerous studies have addressed the solubility of drugs in triglycerides, comparatively few publications have addressed the solubility of drugs in fatty acids, which are the end product of digestion and responsible for the solubility of drug within mixed micelles. The objective of this investigation was to explore the solubility of a poorly water-soluble drug in fatty acids and raise the awareness of the importance of drug solubility in fatty acids. The model API (active pharmaceutical ingredient), a weak acid, is considered a BCS II compound with an aqueous solubility of 0.02 μg/mL and predicted partition coefficient >7. The solubility of API ranged from 120 mg/mL to over 1 g/mL in fatty acids with chain lengths across the range C18 to C6. Hydrogen bonding was found to be the main driver of the solubilization of API in fatty acids. The solubility of API was significantly reduced by water uptake in caprylic acid but not in oleic acid. This report demonstrates that solubility data generated in fatty acids can provide an indication of the solubility of the drug after lipid digestion. This report also highlights the importance of measuring the solubility of drugs in fatty acids in the course of lipid formulation development.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Drug development and industrial pharmacy - 44(2018), 9, Seite 1551-1556 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lee, Yung-Chi [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Fatty acids |
|---|
| Umfang: |
1 Online-Ressource (6 p) |
|---|
| doi: |
10.1080/03639045.2018.1483395 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011100257 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011100257 | ||
| 003 | DE-627 | ||
| 005 | 20230713210655.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230609s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/03639045.2018.1483395 |2 doi | |
| 035 | |a (DE-627)KFL011100257 | ||
| 035 | |a (KFL)prod_LgpH_10.1080/03639045.2018.1483395 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Lee, Yung-Chi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Drug solubility in fatty acids as a formulation design approach for lipid-based formulations: a technical note |c Yung-Chi Lee, Chad Dalton, Brian Regler, David Harris |
| 264 | 1 | |c 2018 | |
| 300 | |a 1 Online-Ressource (6 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Lipid-based drug delivery systems have been intensively investigated as a means of delivering poorly water-soluble drugs. Upon ingestion, the lipases in the gastrointestinal tract digest lipid ingredients, mainly triglycerides, within the formulation into monoglycerides and fatty acids. While numerous studies have addressed the solubility of drugs in triglycerides, comparatively few publications have addressed the solubility of drugs in fatty acids, which are the end product of digestion and responsible for the solubility of drug within mixed micelles. The objective of this investigation was to explore the solubility of a poorly water-soluble drug in fatty acids and raise the awareness of the importance of drug solubility in fatty acids. The model API (active pharmaceutical ingredient), a weak acid, is considered a BCS II compound with an aqueous solubility of 0.02 μg/mL and predicted partition coefficient >7. The solubility of API ranged from 120 mg/mL to over 1 g/mL in fatty acids with chain lengths across the range C18 to C6. Hydrogen bonding was found to be the main driver of the solubilization of API in fatty acids. The solubility of API was significantly reduced by water uptake in caprylic acid but not in oleic acid. This report demonstrates that solubility data generated in fatty acids can provide an indication of the solubility of the drug after lipid digestion. This report also highlights the importance of measuring the solubility of drugs in fatty acids in the course of lipid formulation development | ||
| 653 | |a Solubility | ||
| 653 | |a fatty acids | ||
| 653 | |a solubility parameters | ||
| 653 | |a glycerides | ||
| 653 | |a lipid-based | ||
| 700 | 1 | |a Dalton, Chad |e verfasserin |4 aut | |
| 700 | 1 | |a Regler, Brian |e verfasserin |4 aut | |
| 700 | 1 | |a Harris, David |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug development and industrial pharmacy |d Abingdon : Taylor & Francis Group, 1977 |g 44(2018), 9, Seite 1551-1556 |h Online-Ressource |w (DE-627)KFL000005975 |w (DE-600)2008903-X |w (DE-576)116897511 |x 1520-5762 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2018 |g number:9 |g pages:1551-1556 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/tandf-ejournals-pharmazie/doi.org/10.1080/03639045.2018.1483395 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-TFE | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_LgpH_01 | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2018 |e 9 |h 1551-1556 | ||